Skip to main content

Advertisement

SpringerLink
Log in

Aventis Pasteur Vaccines Containing Inactivated Hepatitis A Virus: A Compilation of Immunogenicity Data

  • Special Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Inactivated hepatitis A vaccines were developed in the 1980s and were introduced during the early 1990s. The Aventis Pasteur (AvP) inactivated hepatitis A virus antigen is used in several different vaccine formulations licensed for adults and children. Presented here are the immunogenicity results compiled from 37 clinical trials performed in 20 different countries between 1991 and 2001 in which these vaccines were administered to adults (16 years of age and over), children (aged 12 months–17 years), and infants (younger than 12 months). The accumulated clinical experience with these hepatitis A virus-containing vaccines demonstrates the excellent immunogenicity of this antigen in a wide range of situations. As with other licensed inactivated hepatitis A vaccines, immunological priming is achieved in virtually all vaccinees after a single-dose primary immunization, and it may be reinforced by a booster vaccination administered 6–36 months after the primary vaccination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. André FE, d’Hondt E, Delem AD, Safary A (1992) Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine—rationale and summary of findings. Vaccine 10 (Suppl 1):160–168

    Google Scholar 

  2. Nalin DR (1995) Vaqta. Drug Fut 20:24–29

    Google Scholar 

  3. Vidor E, Fritzell B, Plotkin, S (1996) Clinical development of a new inactivated hepatitis A vaccine. Infection 24:447–458

    CAS  PubMed  Google Scholar 

  4. Ambrosch F, Wiedermann G, Jonas S, Althaus B, Finkel B, Glück R, Herzog C (1997) Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 15:1209–1213

    Article  CAS  PubMed  Google Scholar 

  5. Feinstone SM, Gust ID (1998) Hepatitis A vaccine. In: Plotkin SA, Orenstein WA (eds) Vaccines. WB Saunders, Philadelphia, pp 650–671

  6. Ambrosch F, Wiedermann G, André FE, Delem AD, Gregor H, Hofmann H, d’Hondt E, Kundi M, Wynen J, Kunz C (1994) Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. J Med Virol 44:452–456

    CAS  PubMed  Google Scholar 

  7. Overbosh D, Peyron F, Picot N, Varichon JP (2001) Immunogenicity and safety of a combined typhoid fever and hepatitis A vaccine: a comparison of the combined vaccine in a dual-chamber syringe presentation versus the monovalent vaccines. In: Program and abstracts of the 7th International Conference on Travel Medicine. Abstract no. 63

  8. Loebermann M, Kollaritsch H, Chappey O, Chambonneau L, Dumas R, Lafrenz M (2001) Immunogenicity and safety of a combined typhoid fever and hepatitis A vaccine in healthy adults. In: Program and abstracts of the 7th International Conference on Travel Medicine. Abstract no. 64

  9. Van Hoecke C, Lebacq E, Beran J, Prymula R, Collard F (1998) Concomitant vaccination against hepatitis A and typhoid fever. J Trav Med 5:116–120

    Google Scholar 

  10. Piazza M, Safary A, Vegnente A, Soncini R, Pensati P, Sardo M, Orlando R, Tosone G, Picciotto L (1999) Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in childhood vaccination programme. Vaccine 17:585–588

    Article  CAS  PubMed  Google Scholar 

  11. Shapiro CN, Letson GW, Kuehn D, Welty TK, Krause D, Lambert S, Margolis HS (1995) Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. H-61

  12. Lieberman JM, Marcy SM, Partridge J, Ward J (1998) Evaluation of a hepatitis A vaccine in infants: effect of maternal antibodies on the antibody response. In: Program and abstracts of the 36th Infectious Diseases Society of America annual meeting. Abstract no. 76

  13. Troisi CL, Hollinger FB, Krause DS, Pickering LK (1997) Immunization of seronegative infants with hepatitis A vaccine (HAVRIX): a comparative study of two dosing schedules. Vaccine 15:1613–1617

    Article  CAS  PubMed  Google Scholar 

  14. Dagan R, Amir J, Mijalovsky A, Kalmanovitch I, Bar-Yochai A, Thoelen S, Safary A, Ashkenazi S (2000) Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Ped Infect Dis J 19:1045–1052

    Article  CAS  Google Scholar 

  15. Lopez EL, Contrini MM, Xifro M, Del C, Ceccoli SC, Cattaneo MA, Zambrano B, Dumas R, Rouyrre N, Weber F (2002) Hepatitis A vaccination of Argentinean infants: comparison of two vaccination schedules. In: Program and abstracts of the 3rd World Congress of Pediatric Infectious Diseases. Abstract no. 25

  16. Lagos R, Munoz A, Dumas R, Pichon S, Zambrano B, Levine M, Vidor E (2003) Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in presence of maternal antibodies. Vaccine 21:3730–3733

    Article  CAS  PubMed  Google Scholar 

  17. Nalin DR, Kuter BJ, Brown L, Patterson C, Calandra GB, Werzberger A, Shouval D, Ellerbeck EF, Block SL, Bishop RP, Wiens B, Schwartz SW, Lewis JA, Sitrin RD, Provost PJ, Miller WJ, Ryan JL (1993) Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J Hepatol 18 (Suppl 2):51–55

    Google Scholar 

  18. Vidor E, Fanget B, Montagnon B, Flehmig B (1993) Preliminary results of the clinical development of a highly purified inactivated hepatitis A vaccine. In: Spiess H (ed) Immunprophylaxe gegen Hepatitis A. Deutsches Grünes Kreuz, Marburg, pp 115–166

  19. Garin D, Vidor E, Wallon M, Fanget B, Brasseur P, Delolme H, Caron F, Mojon M, Gravey A, Humbert G, Flehmig B, Peyron F (1995) Good immunogenicity of GBM strain inactivated hepatitis A vaccine in healthy male adults. Vaccine 13:220–224

    Article  CAS  PubMed  Google Scholar 

  20. Zanetti A, Pregliasco F, Andreassi A, Pozzi A, Vigano P, Cargnel A, Briantais P, Vidor E (1997) Does immunoglobulin interfere with the immunogenicity to Pasteur Mérieux inactivated hepatitis A vaccine? J Hepatol 26:25–30

    Article  CAS  PubMed  Google Scholar 

  21. Walter EB, Hornick RB, Poland GA, Tucker R, Bland CL, Clements DA, Rhamstine CC, Jacobson RM, Brown L, Gress JO, Harris KE, Wiens BL, Nalin DR (1999) Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults. Vaccine 17:1468–1473

    Article  CAS  PubMed  Google Scholar 

  22. Leentvaarkuijpers A, Coutinho RA, Brulein V, Safary A (1992) Simultaneous passive and active immunization against hepatitis A. Vaccine 10 (Suppl 1):138–141

  23. Zaaijer HL, Leentvaarkuijpers A, Rotman H, Lelie PN (1993) Hepatitis A antibody titres after infection and immunization—Implications for passive and active immunization. J Med Virol 40:22–27

    CAS  PubMed  Google Scholar 

  24. Wagner G, Lavanchy D, Darioli R, Pecoud A, Brulein V, Safary A, Frei PC (1993) Simultaneous active and passive immunization against hepatitis A studied in a population of travellers. Vaccine 11:1027–1032

    Article  CAS  PubMed  Google Scholar 

  25. Green MS, Cohen D, Lerman Y, Sjogren MH, Binn LN, Zur S, Slepon R, Robin G, Hoke CH, Bancroft WH, Safary A, Danon Y, Wiener M (1993) Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin. J Infect Dis 168:740–743

    CAS  PubMed  Google Scholar 

  26. Goilav C, Zuckerman JN, Lafrenz M, Vidor E, Lauwers S, Ratheau C, Benichou G, Zuckerman AJ (1995) Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. J Med Virol 46:287–292

    CAS  PubMed  Google Scholar 

  27. Reuman PD, Kubilis P, Hurni W, Brown L, Nalin D (1997) The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine 15:1157–1161

    Article  CAS  PubMed  Google Scholar 

  28. Goubau P, Vangerven V, Safary A, Delem AD, Knops J, d’Hondt E, André FE, Desmyter J (1992) Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine. Vaccine 10 (Suppl 1):114–118

    Google Scholar 

  29. Fisch A, Cadilhac P, Vidor E, Prazuck T, Dublanchet A, Lafaix C (1996) Immunogenicity and safety of a new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route. Vaccine 14:1132–1136

    Article  CAS  PubMed  Google Scholar 

  30. Linglof T, Van Hattum J, Kaplan KM, Corrigan J, Duval I, Jensen E, Kuter B (2001) An open study of subcutaneous administration of inactivated hepatitis A vaccine (Vaqta) in adults: safety, tolerability, and immunogenicity. Vaccine 19:3968–3971

    Article  CAS  PubMed  Google Scholar 

  31. Williams J, Fox-Leyva L, Christensen C, Fisher D, Schlicting E, Snowball M, Negus S, Mayers J, Koller R, Stout R (2000) Hepatitis A vaccine administration: comparison between ject-injector and needle injection. Vaccine 18:1939–1943

    Article  CAS  PubMed  Google Scholar 

  32. Brindle RJ, Morris CA, Berger R, Kurtz JB (1994) Inadequate response to intradermal hepatitis A vaccine. Vaccine 12:483–484

    Article  CAS  PubMed  Google Scholar 

  33. Dumas R, Forrat R, Lang J, Farinelli T, Loutan L (1997) Safety and immunogenicity of a new inactivated hepatitis A vaccine in concurrent administration with a typhoid fever vaccine or a typhoid fever + yellow fever vaccine. Adv Therapy 14:160–167

    CAS  Google Scholar 

  34. Beeching N, Clarke P, Kitchin N, Pirmohamed J, Veitch K, Weber F (2003) Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults. J Travel Med (in press)

  35. Beran J, Chlibek R, Weber F (2003) A combined dual chamber typhoid/hepatitis A vaccine as a booster dose in hepatitis A primed adults. Vaccine 21:4650–4654

    Article  CAS  PubMed  Google Scholar 

  36. Zuckerman J, Peyron F, Wallon M, Gay F, Delolme H, Briantais P, Vidor E (1997) Comparison of the safety and immunogenicity of two inactivated hepatitis A vaccines. Adv Therapy 14:116–124

    CAS  Google Scholar 

  37. Vidor E, Ratheau C, Briantais P, Vuillier D (1998) Comparison of two immunization schedules with an inactivated hepatitis A vaccine (Avaxim). J Travel Med 5:167–172

    CAS  PubMed  Google Scholar 

  38. Lolekha S, Pratuangtham S, Punpanich W, Bowonkiratikachorn P, Chimabutra K, Weber F (2003) Immunogenicity and safety of two doses of a pediatric hepatitis A vaccine in Thai children: comparison of 3 vaccination schedules (0–6, 0–12 or 0–18 Months). J Trop Ped 49:333–339

    Google Scholar 

  39. Hornick R, Tucker R, Kaplan KM, Eves KA, Banerjee D, Jensen E, Kuter B (2001) A randomized study of a flexible booster dosing regimen of Vaqta in adults: safety, tolerability, and immunogenicity. Vaccine 19:4727–4731

    Article  CAS  PubMed  Google Scholar 

  40. Kanra G, Yalcin SS, Kara A, Ozmert E, Yurdakok K (2002) Hepatitis A booster vaccine in children after infant immunization. Ped Infect Dis J 21:727–730

    Article  Google Scholar 

  41. Iwarson S, Lindh M (2002) Excellent booster response 4–6 y after a single primary dose of an inactivated hepatitis A vaccine. Scand J Infect Dis 34:110–111

    Article  PubMed  Google Scholar 

  42. Kanra G, Yalcin SS, Ceyhan M, Yurdakok K (2000) Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children. Turk J Pediatr 42:105–108

    CAS  PubMed  Google Scholar 

  43. Landry P, Tremblay S, Darioli R, Genton B (2001) Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose. Vaccine 19:399–402

    Article  Google Scholar 

  44. Cederna JB, Klinzman D, Stapleton JT (1999) Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine. Vaccine 18:892–898

    Article  CAS  PubMed  Google Scholar 

  45. Zuckerman JN, Kirkpatrick CT, Huang M (1998) Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A. J Travel Med 5:18–22

    CAS  PubMed  Google Scholar 

  46. Clarke P, Kitchin N, Souverbie F (2001) A randomised comparison of two inactivated hepatitis A vaccines, Avaxim and Vaqta, given as a booster to subjects primed with Avaxim. Vaccine 19:4429–4433

    Article  CAS  PubMed  Google Scholar 

  47. Bryan JP, Henry CH, Hoffman AG, South-Paul JE, Smith JA, Cruess D, Spieker JM, De Medina M (2000) Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 19:743–750

    Article  CAS  PubMed  Google Scholar 

  48. Herzog C, Angst F, Beck BR, Bovier P, Farinelli T, Glueck R, Hatz C, Loutan L, Steffen R, Zellmeyer M (1997) Boosting healthy travelers with a virosome-formulated hepatitis A vaccine after basic immunization with an alum-adsorbed hepatitis A vaccine. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no. 132

  49. Goilav C, Zuckerman J, Lafrenz M, Vidor E, Briantais P, Lauwers S, Ratheau C, Benichou G, Zuckerman A (1997) Persistence of antibodies after inactivated hepatitis A vaccines in a comparative study. J Infect 34:158

    CAS  Google Scholar 

  50. Van Herck K, Beutels P, Van Damme P, Beutels M, Van den Dries J, Briantais Ph, Vidor E (2000) Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 60:1–7

    Article  PubMed  Google Scholar 

  51. Werzberger A, Kuter B, Nalin D (1998) Six years’ follow-up after hepatitis A vaccination. N Engl J Med 338:1160

    Article  CAS  Google Scholar 

  52. Maiwald H, Jilg W, Bock HL, Löscher T, Sonnenburg FV (1997) Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine. Vaccine 15:346–348

    Article  CAS  PubMed  Google Scholar 

  53. Van Damme P, Thoelen S, Cramm M, Degroote K, Safary A, Meheus A (1994) Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 44:446–451

    PubMed  Google Scholar 

  54. Wiedermann G, Kundi M, Ambrosch F (1998) Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0–6 schedule). Acta Trop 69:121–125

    Article  CAS  PubMed  Google Scholar 

  55. Van Herck K, Van Damme P (2001) Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 63:1–7

    Article  PubMed  Google Scholar 

  56. Wiens BL, Bohidar NR, Pigeon JG, Egan J, Hurni W, Brown L, Kuter BJ, Nalin DR (1996) Duration of protection from clinical hepatitis A disease after vaccination with Vaqta. J Med Virol 49:235–241

    Article  CAS  PubMed  Google Scholar 

  57. Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C (2002) Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 68:489–493

    Article  CAS  PubMed  Google Scholar 

  58. Ashur Y, Adler R, Rowe M, Shouval D (1999) Comparison of immunogenicity of two hepatitis A vaccines—Vaqta® and Havrix®—in young adults. Vaccine 17:2290–2296

    Article  CAS  PubMed  Google Scholar 

  59. Braconier J, Wennerholm S, Norrby R (1999) Comparative immunogenicity and tolerance of Vaqta® and Havrix®. Vaccine 17:2181–2184

    Article  CAS  PubMed  Google Scholar 

  60. Bovier P, Althaus B, Glueck R, Chippaux A, Loutan L (1999) Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines. J Travel Med 6:228–233

    CAS  PubMed  Google Scholar 

  61. Williams J, Bruden D, Cagle H, McMahon B, Negus S, Christensen C, Snowball M, Bulkow L, Fox-Leyva L (2003) Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine 21:3208–3211

    Article  CAS  PubMed  Google Scholar 

  62. Peetermans J (1992) Production, quality control and characterization of an inactivated hepatitis A vaccine. Vaccine 10 (Suppl 1):99–101

    Google Scholar 

  63. Armstrong ME, Giesa PA, Davide JP, Redner F, Waterbury JA, Rhoad AE, Keys RD, Provost PJ, Lewis JA (1993) Development of the formalin-inactivated hepatitis A vaccine, Vaqta from the live attenuated virus strain CR326F. J Hepatol 18 (Suppl 2):20–26

    Google Scholar 

  64. Gluck R, Mischler R, Brantschen S, Just M, Althaus B, Cryz SJ (1992) Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest 90:2491–2495

    CAS  PubMed  Google Scholar 

  65. Winokur PL, Stapleton JT (1992) Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 14:580–586

    CAS  PubMed  Google Scholar 

  66. Vidor E, Xueref C, Blondeau C, Bajard A, Francon A, Goudeau A, Peyron F, Brasseur P, Zuckerman A (1996) Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine. Biologicals 24:235–242

    Article  CAS  PubMed  Google Scholar 

  67. Centers for Disease Control and Prevention (1999) Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 48(RR-12):1–31

  68. Direction générale de la santé. Comité technique des vaccinations (1999) La vaccination contre l’hépatite A. In: Guide des vaccinations pp 99–103

  69. Lopez EL, Del Carmen X, Torrado LE, De Rosa MF, Gomez R, Dumas R, Wood SC, Contrini M (2001) Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children. Pediatr Infect Dis J 20:48–52

    Article  CAS  PubMed  Google Scholar 

  70. Dagan R, Greenberg D, Goldenbertg-Gehtman P, Vidor E, Briantais P, Pinsk V, Athias O, Dumas R (1999) Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine. Vaccine 17:1919–1925

    Article  CAS  PubMed  Google Scholar 

  71. Chadha MS, Chitambar SD, Shaikh NJ, Arankalle VA (1999) Exposure of Indian children to hepatitis A virus and vaccination age. Indian J Med Res 109:11–15

    CAS  PubMed  Google Scholar 

  72. Castillo de Febres C, Petrola C de, Escalona N de, Estopinan M, Bordones G, Zambrano B, Garcia A, Dumas R (2000) Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children. Vaccine 18:656–664

    Article  Google Scholar 

  73. Lee CY, Huang LM, Lee PI, Chiu HH, Dumas R, Milcamps B, Lin W (2000) Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children. Southeast Asian J Trop Med Public Health 31:29–36

    CAS  PubMed  Google Scholar 

  74. Boutin JP, Buisson Y, Chapuis P, Delolme H, Germanetto P, Lamarque D, Lemardeley P, Lemoal JJ, Merouze F, Vidor E (1996) Evaluation of the safety and immunogenicity of a new inactivated hepatitis A vaccine in the French army. Int Rev Armed Forces Med Serv 69:249–254

    Google Scholar 

  75. Vimolket T, Theamboonlers A, Dumas R, Milcamps B, Forrat R, Poovorawan Y (1998) Immunogenicity and safety of a new inactivated hepatitis A vaccine in Thai young adults. Southeast Asian J Trop Med Public Health 29:779–785

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank all of the subjects who agreed to enroll in the clinical trials described here, under the supervision and solicitation of the investigators who performed the studies. In addition, this work would have not been possible without the help of many people within several departments of Aventis Pasteur. All clinical trials included here were conducted in accordance with Good Clinical Practices, the Helsinki declaration, and with local regulations applying to the protection of human subjects involved in medical research.

Author information

Authors and Affiliations

  1. Aventis Pasteur, Medical Department, Clinical Development, 57 Avenue Leclerc, 69007, Lyon, France

    E. Vidor & R. Dumas

  2. Aventis Pasteur, Medical Department, Clinical Operations, 57 Avenue Leclerc, 69007, Lyon, France

    V. Porteret & F. Bailleux

  3. Aventis Pasteur, Medical Department, Global Medical Affairs, 57 Avenue Leclerc, 69007, Lyon, France

    K. Veitch

Authors
  1. E. Vidor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Dumas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Porteret
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Bailleux
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Veitch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Vidor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vidor, E., Dumas, R., Porteret, V. et al. Aventis Pasteur Vaccines Containing Inactivated Hepatitis A Virus: A Compilation of Immunogenicity Data. Eur J Clin Microbiol Infect Dis 23, 300–309 (2004). https://doi.org/10.1007/s10096-003-1094-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-003-1094-0

Keywords

Search

Navigation